Examples of behavioral changes suggest the power of messaging when disseminated from a bully pulpit. Kennedy’s conspicuous visibility reinforces his reach.
Trump’s orders move the U.S. a few steps closer to more widespread research on and use of two sets of controversial yet promising drugs, psychedelic and cannabis products
AI‑designed intracellular antibody fragments can stay stable inside cells and bind misfolded proteins, opening new treatment routes for diseases.
Nearly 200 blood proteins rise and fall across the menstrual cycle, enabling a test that pinpoints cycle day and links it to risks like fibroids and heavy bleeding.
An overactive immune switch in the placenta may drive preeclampsia; blocking it in models reverses key disease pathways, pointing toward targeted therapies.
Variants in GLP‑1 and GIP receptor genes partly determine weight loss and nausea risk on GLP‑1 drugs, signaling a shift from one‑size‑fits‑all treatment.
Clinical genome sequencing now delivers genetic diagnoses for about 1 in 4 suspected rare disease patients, guiding targeted care and shaping newborn screening worldwide.
Quarterly RNA drug plozasiran turns off a liver gene, sharply lowering life‑threatening pancreatitis attacks in a rare genetic disorder.
Serially cloned mice hit a genetic “dead end” by generation 58, underscoring that sex evolved for variation, purging harmful mutations and keeping lineages viable.
Programmable cell‑like particles seek out drug‑resistant bacteria, inject lethal payloads, and spare beneficial microbes.